BRAF and non-small cell lung carcinoma: For instance, a patient with NSCLC with wt BRAF and a KRAS G12C mutation in the tissue and cfDNA (3.80%) was also found to have a low frequency BRAF V600K mutation in cfDNA (0.03) at the time of disease progression while taking a MEK inhibitor for 3.7 months.